HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

Skin-Care Devices Are Next $1 Bil. Market

You may also be interested in...



L’Oreal Powering Down Clarisonic After 16 Years Of Innovation, More Than 15 Million Devices Sold

The decision to close Clarisonic follows a 234m impairment charge recorded in 2016 and comes as L’Oreal faces tough strategic decisions in a global economy ravaged by the COVID-19 crisis.

FDA Warns Quasar For Lack Of Proper Skin-Care Device Clearance; Firm Cites Mix-Up

An FDA warning letter to Quasar Bio-Tech suggests the marketer of Baby Quasar and Quasar MD lacks correct 510(k) device clearance and is improperly marketing its home-use skin-care device products. Quasar maintains it holds the correct clearances, and that FDA may be confused by its product nomenclature.

L’Oreal USA Plugs Into Device Category With PBL/Clarisonic Acquisition

Related Content

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel